Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

NCT04884035 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

224

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, B-Cell

Interventions

DRUG: CC-220
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone
DRUG: CC-99282
DRUG: Polatuzumab vedotin
DRUG: Rituximab

Sponsor

Celgene